Lewis Cantley, PhD, the cancer researcher best known for his discovery of the PI3K pathway and his groundbreaking work on cancer metabolism, will be joining the Dana-Farber Cancer Institute in February 2022.
Laurie Glimcher, MD
Dr. Cantley’s move from his current position as Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College was announced by Laurie Glimcher, MD, President and Chief Executive Officer of the Dana-Farber Cancer Institute. Dr. Glimcher hailed Dr. Cantley’s impending arrival as a faculty member in the Department of Cancer Biology, which returns the former Harvard Professor to the center of things during an unprecedented biotech boom.
Contributions to the Cancer World
Dr. Cantley has accumulated a long list of major scientific prizes and is also a key figure in the biotech world, lending his research to the recent launch of Volastra Therapeutics. That venture, which attracted backing from Polaris, is pursuing an ambitious goal of establishing an entirely new approach to cancer therapy.
David Schenkein, MD
Bradley Bernstein, MD, PhD
Earlier, Dr. Cantley gained attention as a cofounder at Agios, working closely with David Schenkein, MD, and occupying a seat on the Agios board as well as the scientific advisory board, which continues to this day.
“Lew is a luminary scientist who is a friend to many in our community,” noted Dr. Glimcher and Bradley Bernstein, MD, PhD, who heads the department. “We are confident that he will be a terrific colleague and mentor for our faculty and trainees.”
